Zacks Investment ResearchFri, 12 Jun 2026 16:31:09 GMTWhy Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?ALT-1.19%
Seeking AlphaWed, 10 Jun 2026 14:32:28 GMTAltimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptALT-1.19%
MarketBeatWed, 10 Jun 2026 13:05:26 GMTAltimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data NearALT-1.19%
Zacks Investment ResearchMon, 08 Jun 2026 17:11:29 GMTALT Stock Guide to Pemvidutide's MASH, AUD and ALD SetupALT-1.19%
Zacks Investment ResearchMon, 08 Jun 2026 17:11:16 GMTALT and the Rise of Dual Agonists Targeting Liver DiseaseALT-1.19%
Zacks Investment ResearchMon, 08 Jun 2026 16:55:53 GMTIs Altimmune Worth Buying Ahead of 2026 Catalysts?ALT-1.19%
MarketBeatFri, 05 Jun 2026 03:10:16 GMTAltimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH TrialALT-1.19%
Zacks Investment ResearchFri, 22 May 2026 17:15:29 GMTHere's Why You Should Add Altimmune Stock to Your Portfolio NowALT-1.19%
Zacks Investment ResearchThu, 14 May 2026 15:46:15 GMTAltimmune's Q1 Loss Narrower Than Expected, Revenues NilALT-1.19%
Seeking AlphaThu, 14 May 2026 04:40:44 GMTAltimmune, Inc. (ALT) Q1 2026 Earnings Call TranscriptALT-1.19%
Zacks Investment ResearchThu, 23 Apr 2026 18:16:08 GMTAltimmune Catalysts: 2026 Data Readouts and Financing RisksALT-1.19%
Zacks Investment ResearchThu, 23 Apr 2026 18:10:59 GMTALT Stock: What Pemvidutide Means for MASH, AUD and ALDALT-1.19%
Zacks Investment ResearchThu, 23 Apr 2026 18:06:09 GMTIs Altimmune a Buy Before Phase III MASH Starts in 2026?ALT-1.19%
